GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ICU Medical Inc (NAS:ICUI) » Definitions » EBIT
中文

ICU Medical (ICU Medical) EBIT : $24 Mil (TTM As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is ICU Medical EBIT?

ICU Medical's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $24 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ICU Medical's annualized ROC % for the quarter that ended in Dec. 2023 was -0.26%. ICU Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ICU Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.64%.


ICU Medical EBIT Historical Data

The historical data trend for ICU Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ICU Medical EBIT Chart

ICU Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 115.26 99.25 124.04 -43.60 24.43

ICU Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.71 10.88 2.97 20.56 -9.98

Competitive Comparison of ICU Medical's EBIT

For the Medical Instruments & Supplies subindustry, ICU Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ICU Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ICU Medical's EV-to-EBIT falls into.



ICU Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ICU Medical  (NAS:ICUI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ICU Medical's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-21.772 * ( 1 - 53.25% )/( (3866.99 + 3815.891)/ 2 )
=-10.17841/3841.4405
=-0.26 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4376.864 - 310.876 - ( 198.998 - max(0, 464.043 - 1219.408+198.998))
=3866.99

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4378.439 - 307.825 - ( 254.723 - max(0, 481.838 - 1221.272+254.723))
=3815.891

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

ICU Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-39.9/( ( (685.343 + max(597.635, 0)) + (685.525 + max(535.291, 0)) )/ 2 )
=-39.9/( ( 1282.978 + 1220.816 )/ 2 )
=-39.9/1251.897
=-3.19 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(161.797 + 759.622 + 74.721) - (310.876 + 28.768 + 58.861)
=597.635

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(161.566 + 709.36 + 75.042) - (307.825 + 31.64 + 71.212)
=535.291

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ICU Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=24.427/3831.064
=0.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ICU Medical EBIT Related Terms

Thank you for viewing the detailed overview of ICU Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ICU Medical (ICU Medical) Business Description

Traded in Other Exchanges
N/A
Address
951 Calle Amanecer, San Clemente, CA, USA, 92673
ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017, and Smiths Medical from Smiths Group in 2022. It holds top-tier positions in its original reporting segments: infusion consumables (25% of 2022 revenue), IV solutions (16%), infusion systems (15%), and critical care (2%) as well as its new Smiths segments: Smiths infusion systems (15%), vascular access (14%), and vital care (12%). The combined entity remains primarily U.S. focused, generating over 64% of its sales domestically.
Executives
Daniel Woolson officer: VP, GM-Infusion Capital ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Christian B. Voigtlander officer: Chief Operating Officer 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Vivek Jain director, officer: Chairman and CEO ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Virginia Ruth Sanzone officer: VP, General Counsel 951 CALLE AMANECER, SAN CLEMENTE CA 92673
George A Lopez director, officer: Chairman, other: Chairman C/O ICU MEDICAL, 951 CALLE AMANECER, SAN CLEMENTE CA 92673
William Seeger director 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Smiths Group International Holdings Ltd 10 percent owner C/O SMITHS GROUP PLC, 11-12 ST. JAMES'S SQUARE, 4TH FLOOR, LONDON X0 SW1Y 4LB
Group Plc Smiths 10 percent owner 765 FINCHKEY ROAD, LONDON X0 00000
Kolleen T Kennedy director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Robert S Swinney director C/O ICU MEDICAL, 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Laurie Hernandez director 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Brian Michael Bonnell officer: Chief Financial Officer ICU MEDICAL INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Scott E Lamb officer: Controller ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Kevin J Mcgrody other: Controller ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673